Protective effect of paraoxonase 1 of high-density lipoprotein in type 2 diabetic patients with nephropathy

Nephrology

Volumn 14, Issue 5, 2009, Pages 514-520

  Li, Chengjiang ^a   Gu, Qing ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

High density lipoprotein; Nephropathy; Paraoxonase 1; Peroxide; Type 2 diabetes

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATION; PRIORITY JOURNAL;

ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 68349092854     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01035.x     Document Type: Article

References (32)

1. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. JAMA 1986 256 : 2835 8.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 1977 62 : 707 14.
3. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ. Res. 2004 95 : 764 72.
4. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 2001 42 : 1308 17.
5. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl Acad. Sci. USA 1992 89 : 10316 20.
6. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979 241 : 2035 8.
7. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: The Framingham study. Circulation 1979 59 : 8 13.
8. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 1997 20 : 935 42.
9. Jay D, Hitomi H, Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic. Biol. Med. 2006 40 : 183 92.
10. Scheffer PG, Bos G, Volwater HG, Dekker JM, Heine RJ, Teerlink T. Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients. Diabet. Med. 2003 20 : 563 7.
11. Phillips C, Owens D, Collins P, Tomkin GH. Low density lipoprotein non-sterified fatty acids and lipoprotein lipase in diabetes. Atherosclerosis 2005 181 : 109 14.
12. Ujihara N, Sakka Y, Takeda M et al. Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res. Clin. Pract. 2002 58 : 109 14.
13. Shimada K, Mokuno H, Matsunaga E et al. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. Diabetes Care 2004 27 : 843 4.
14. Betteridge DJ. Diabetic dyslipidaemia. Eur. J. Clin. Invest. 1999 29 : 12 16.
15. Mastorikou M, Mackness M, Mackness B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes 2006 55 : 3099 103.
16. Nobecourt E, Jacqueminet S, Hansel B et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: Relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005 48 : 529 38.
17. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler. Thromb. Vasc. Biol. 1999 19 : 2226 33.
18. Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: Pharmacological and nutritional influences. Curr. Opin. Lipidol. 2005 16 : 393 9.
19. Mackness B, Mackness MI, Arrol S et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998 139 : 341 9.
20. James RW, Leviev I, Ruiz J, Passa P, Froguel P, Garin MC. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 2000 49 : 1390 93.
21. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K. Serum arylesterase/diazoxonase activity and genetic polymorphisms in patients with type 2 diabetes. Metabolism 2000 49 : 1400 405.
22. Mackness B, Hine D, McElduff P, Mackness M. High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 2006 186 : 396 401.
23. Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J. Clin. Endocrinol. Metab. 2003 88 : 1711 16.
24. Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis 2006 187 : 74 81.
25. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 1998 101 : 1581 90.
26. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2003 23 : 1881 8.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951 193 : 265 75.
28. Ferretti G, Marchionni C, Bacchetti T, Galeazzi T, Dousset N. Effect of aluminium on lipid peroxidation of human high density lipoproteins. Free Radic. Res. 2003 37 : 515 21.
29. Zhou H, Tan KC, Shiu SW, Wong Y. Increased serum advanced glycation and products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. Nephrol. Dial. Transplant 2008 23 : 927 33.
30. Hofer SE, Bennetts B, Chan AK et al. Association between PON 1 polymorphisms, PON activity and diabetes complications. J. Diabetes Complications. 2006 20 : 322 8.
31. Ferretti G, Bacchetti T, Moroni C et al. Paraoxonase activity in high-density lipoproteins: A comparison between healthy and obese females. J. Clin. Endocrinol. Metab. 2005 90 : 1728 33.
32. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: A comparison between healthy subjects and type 1 diabetic patients. J. Clin. Endocrinol. Metab. 2004 89 : 2957 62.